An interaction between two proteins — one called Rhes and the other Slc4a7 — helps to build tiny tunnels between…
Articles by Marisa Wexler, MS
Roflumilast, an oral therapy approved in the U.S. to treat inflammatory lung disease, was shown to reduce brain inflammation, promote…
U.K. biotech company Harness Therapeutics has selected HRN001 as its lead experimental treatment candidate for Huntington’s disease. “The…
Nine months of treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 appears to have slowed disease progression relative to its…
Comedian and actor Will Forte is teaming up with Teva Pharmaceuticals to raise awareness about Huntington’s disease (HD).
Loqus23 Therapeutics said it is advancing LQT-23 for development as a first-in-class oral treatment for Huntington’s disease. The…
The team at Huntington’s Disease News covered the latest community developments and updates in research related to Huntington’s disease throughout…
The California Institute for Regenerative Medicine (CIRM) — a state agency created to advance novel treatments for serious medical…
Certain antipsychotic medications, including the Huntington’s approved therapy tetrabenazine (sold as Xenazine in the U.S., with generics available), significantly…
Complex fatty molecules called gangliosides are key to the formation of cellular shipping containers that help brain nerve cells get…